Dyne Therapeutics, Inc. (DYN) Stock Score, Valuation & Financial Research

Dyne Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DYN

Dyne Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 15.40. These figures are a research snapshot, not a buy or sell recommendation.

What Dyne Therapeutics, Inc. does

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Dyne Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and debt financing to fund the research and development of its proprietary FORCE platform, which is designed to deliver therapeutics for genetically driven neuromuscular diseases.

Products and services

  • The company is developing a pipeline of product candidates using its FORCE platform, including DYNE-101 for myotonic dystrophy type 1 (DM1), DYNE-251 for Duchenne muscular dystrophy (DMD), and DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD).

Customer types

Patients with genetically driven neuromuscular diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its product candidates for preclinical and clinical testing. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company faces substantial competition from various biotechnology and pharmaceutical companies that are developing or commercializing products for neuromuscular diseases. Source

Business strengths to evaluate

  • Proprietary FORCE platform technology Source

Business risks and research considerations

  • Need for substantial additional funding Source
  • Clinical development and regulatory approval uncertainty Source
  • Reliance on third-party manufacturers and service providers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DYN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 15.40
Market capitalization:
2.88B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -519.41M
Free cash flow:
USD -405.13M
Cash:
USD 676.11M
Total debt:
USD 19.87M
EPS:
USD -3.33

What stands out

  • Free cash flow is USD -405.13M, negative for the stored period.
  • The balance sheet shows USD 676.11M of cash versus USD 19.87M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 656.24M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DYN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DYN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DYN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DYN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DYN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DYN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.